Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) initiated dosing of patients in a Phase 1 clinical trial of its hepatitis C treatment ACH-3422 and announced the lifting of a clinical hold on another hepatitis C drug sovaprevir. The stock price leaped $2.40 to $6.65.
Achillion Pharmaceuticals initiates dosing
June 10, 2014 at 12:48 PM EDT
